CMPX - NASDAQ
Compass Therapeutics, Inc.
$2.13
+2.4%Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
At a Glance
Live Snapshotcmpx
Total Assets
Last Annual Value
219.59M
3-Year CAGR
3%
5-Year CAGR
33%
10-Year CAGR
13%
Compass Therapeutics, Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Compass Therapeutics, Inc. NASDAQ:CMPX | 219.59M | 11.9% | 7.4% | N/A | |
 Ocugen, Inc. NASDAQ:OCGN | 43.52M | -12.3% | -16.3% | 1.9% | |
 Omeros Corporation NASDAQ:OMER | 325.63M | -4.9% | -4.9% | 17.1% | |
 Monopar Therapeutics Inc. NASDAQ:MNPR | 140.72B | 2575.8% | 485.1% | 194.2% | |
 4D Molecular Therapeutics, Inc. NASDAQ:FDMT | 566.71M | 18.6% | 9.9% | N/A | |
 Fulcrum Therapeutics, Inc. NASDAQ:FULC | 366.28M | 12.4% | 9.3% | N/A | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 172.25M | -18.0% | -12.9% | 121.7% | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 71.12M | 16.0% | -8.3% | -6.6% | |
 Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX | 184.99M | -6.9% | 6.2% | -9.0% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 335.38M | 22.3% | 4.3% | 29.8% |
Compass Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your CMPX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.